Pretreatment | Starting CDCA treatment | 15 days after treatment | 1 months after treatment | 4 months after treatment | 8 months after treatment | 1 year–8 months after treatment | |
---|---|---|---|---|---|---|---|
ALT (7–40U/L) | 133 | 127 | 127 | 104 | 74.9 | 47.4 | 24.6 |
AST (13–35U/L) | 206 | 129 | 115 | 122 | 64.2 | 47.7 | 35.5 |
TBIL (5–21 μmol/L) | 300 | 183 | 119.4 | 67.6 | 6 | 5.2 | 4.7 |
DBIL (0–3.4 μmol/L) | 150.4 | 78 | 54.5 | 29.2 | 2.9 | 2.1 | 1.6 |
TBA (0–10 μmol/L) | 100.9a | 33.6b | 54.5 | 65.2 | 12.8 | 4 | 4.9 |
ALP (35–135U/L) | 974 | 742 | 509 | 536 | 186 | 236 | 197 |
γ-GT (7–45U/L) | 27 | 26 | 94 | 183 | 132.7 | 34.1 | 18.4 |
ALB (35–45 g/L) | 33 | 31 | 37 | 35 | 46.7 | 46.2 | 44.5 |
PT (9–12.5S) | 29 | 19.7 | 17.3 | 15.5 | 11 | 12.8 | 13.3 |
APTT (25.4–38.4S) | 75.1 | 47.8 | 46 | 37.9 | 41.7 | 35 | 34.2 |
INR (0.77–1.25) | 2.59 | 1.75 | 1.51 | 1.35 | 0.94 | 0.93 | 1 |
FIB (2.38–4.98 g/L) | 1.42 | 0.98 | 1.49 | 3.33 | 1.64 | 2.13 | 2.16 |